Australia discovers and trials, then sells before the value arrives. The gap is not science or talent but the few hundred million dollars a phase three trial costs – and who is willing to fund it.
Startup · Topic
Australia Company Stories
Expert guides, analysis and tool comparisons on Australia Company Stories from the kurums.com Startup desk — written for business decision-makers and updated as the market moves.
- 55 guides
- 11 subtopics
- Updated Aug 1, 2026
Mining & Resources 5
Property & Construction 5
Agribusiness, Wine & Food Exports 5
Tech Startups & Unicorns 5
Telecom, Media & Digital 5
Airlines, Transport & Infrastructure 5
Superannuation & Investment 5
Retail & Consumer 5
Energy, LNG & Utilities 5
Banking & Financial Services 5
Healthcare & Biotech 5
Latest in Australia Company Stories
How Australia Decides What Medicines Cost
A medicine can be approved as safe and effective in Australia and still be unavailable, because a second committee decides whether it is worth the money. How PBS cost-effectiveness assessment works.
Australian Pathology: A Medical Business That Runs on Logistics
A pathology lab processes each extra sample for almost nothing, so volume decides everything. Why the sector consolidated, why collection centre location is contested, and why Medicare sets the price.
Cochlear and ResMed: Why the Device Sale Is Not the Business
A Cochlear implant creates a customer for seventy years. A ResMed device creates a consumables relationship for decades. Why both Australian device companies are annuities rather than manufacturers.
CSL: How a 1916 Government Laboratory Became a Global Plasma Giant
CSL was created in 1916 because Australia was too isolated to import vaccines. It is now a US$15.5 billion plasma therapeutics company – and its moat is a collection network, not a molecule.
Why Australian Builders Go Broke While Busy
A builder can be fully booked, reporting profit, and insolvent at the same time. The fixed-price contract mechanism behind 2,800 Australian construction failures, and the warning signs that precede them.
All guides
Australian REITs Explained: Why Cap Rates Matter More Than Buildings
A building with unchanged rent can lose a fifth of its value because bond yields moved. How cap rates and gearing drive Australian listed property, and why office and industrial diverged so sharply.
Lendlease: When Great Projects Do Not Make a Good Business
Lendlease delivered landmark urban regeneration in London, New York and Milan. The projects were good; the returns were not. Why integrated development, construction and investment failed.
Australia’s Housing Target Is Failing, and Approvals Are Not the Reason
A record 243,864 dwellings under construction and only 43,816 completed in a quarter. Australia is 112,365 homes behind its target, and the bottleneck is capacity to build, not permission to.
Goodman Group: How a Warehouse Developer Became a Data Centre Company
Goodman bought industrial land near cities for warehouses. With AI driving demand and grid capacity the constraint, those same sites became the scarcest input in the data centre build-out.
Australia’s Water Market: How a River System Became a Tradeable Asset
Australia separated water rights from land title and built one of the world’s most sophisticated water markets. How entitlements and allocations work, and why efficiency and community viability keep colliding.
Australian Grain: The Business Where Rainfall Writes the Annual Report
Silos and port terminals cost the same whether the harvest is huge or nonexistent. Why Australian grain handling has extreme operating leverage, and what the A$101bn to A$73bn forecast means.